Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a

Autor: H. Vrenken, M. Battaglini, M. L. de Vos, G. J. Nagtegaal, B. C. A. Teixeira, A. Seitzinger, D. Jack, M. P. Sormani, B. M. J. Uitdehaag, A. Versteeg, G. Comi, L. Kappos, N. De Stefano, F. Barkhof

Publikováno v: Vrenken, H, Battaglini, M, de Vos, M L, Nagtegaal, G J, Teixeira, B C A, Seitzinger, A, Jack, D, Sormani, M P, Uitdehaag, B M J, Versteeg, A, Comi, G, Kappos, L, de Stefano, N & Barkhof, F 2023, ' Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a ', Journal of Neurology, vol. 270, no. 4, pp. 2271-2282 . https://doi.org/10.1007/s00415-022-11554-5
Journal of Neurology, 270(4), 2271-2282. D. Steinkopff-Verlag

Objective Evaluate the effect of subcutaneous interferon β-1a (sc IFN β-1a) versus placebo on the evolution of T1-weighted MRI lesions and central brain atrophy in in patients with a first clinical demyelinating event (FCDE). Methods Post hoc analy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a014c8dbb91fb175353e359ef889c06
https://research.vumc.nl/en/publications/8333bc63-4499-4df6-ac17-b62e263ea3a8

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Autor: R. Zanin, A. Seferian, N. Brolatti, A. Govoni, L. Edel, A. Jollet, M. Del Sole, Arseniy Lavrov, M.T. Arnoldi, E. De Vos, Eugenio Mercuri, L. Antonaci, G. Coratti, M. Pedemonte, Haojun Ouyang, K. Groves, O. Schneider, M. Foa, Volker Straub, A.C. Defeldre, G. Comi, Stefania Corti, V. Parente, A. Jonas, R.M. Lofra, Laurent Servais, Riccardo Masson, L. Buscemi, Nicolas Deconinck, S. De Lucia, Aurore Daron, M.C. Pera, Claudio Bruno, E. Pagliano, S. Mouffak, Nuno Mendonca, A. Vanlander, Deepa H. Chand, E. Thompson, H. Van Ruiten, V. Tahon, Giovanni Baranello, S. Tachibana, M. Pane, S. Morando, Francesco Muntoni, R. de Sanctis, V. Schembri, F. Dal Farra, A. Mandelli, Odile Boespflug-Tanguy, Sitra Tauscher-Wisniewski, M. Scoto, F. Abel, F. Magri

Publikováno v: The Lancet Neurology. 20:832-841

Summary Background Spinal muscular atrophy is a rare, autosomal recessive, neuromuscular disease caused by biallelic loss of the survival motor neuron 1 (SMN1) gene, resulting in motor neuron dysfunction. In this STR1VE-EU study, we aimed to evaluate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::639ade8f946ff94088f210d64c6a1b0d
https://doi.org/10.1016/s1474-4422(21)00251-9

Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients

Autor: Melissa Sorosina, Ferdinando Clarelli, P. Provero, G. Comi, F. Martinelli Boneschi, Laura Ferrè, Federica Esposito, Massimo Filippi, Elisabetta Mascia, Linda Ottoboni, Giacomo Sferruzza, Silvia Santoro, Lucia Moiola, Vittorio Martinelli

Publikováno v: Molecular Neurobiology. 58:4816-4827

Fingolimod (FTY), a second-line oral drug approved for relapsing remitting Multiple Sclerosis (RRMS) acts in preventing lymphocyte migration outside lymph nodes; moreover, several lines of evidence suggest that it also inhibits myeloid cell activatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7903890ab5ae04a8d7b87ec0bc2e22b7
https://doi.org/10.1007/s12035-021-02465-z